1. Home
  2. III vs ALLO Comparison

III vs ALLO Comparison

Compare III & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Information Services Group Inc.

III

Information Services Group Inc.

HOLD

Current Price

$5.34

Market Cap

251.4M

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.46

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
III
ALLO
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
251.4M
252.9M
IPO Year
2007
2018

Fundamental Metrics

Financial Performance
Metric
III
ALLO
Price
$5.34
$1.46
Analyst Decision
Buy
Buy
Analyst Count
1
11
Target Price
$7.00
$8.67
AVG Volume (30 Days)
285.5K
2.4M
Earning Date
11-03-2025
11-06-2025
Dividend Yield
3.35%
N/A
EPS Growth
N/A
N/A
EPS
0.19
N/A
Revenue
$241,289,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.84
$100.00
P/E Ratio
$28.27
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.95
$0.86
52 Week High
$6.45
$3.78

Technical Indicators

Market Signals
Indicator
III
ALLO
Relative Strength Index (RSI) 50.21 67.33
Support Level $4.98 $1.20
Resistance Level $5.25 $1.35
Average True Range (ATR) 0.18 0.09
MACD 0.01 0.03
Stochastic Oscillator 84.44 89.71

Price Performance

Historical Comparison
III
ALLO

About III Information Services Group Inc.

Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: